CRX (Cone-Rod Homeobox) antibody targets the CRX protein, a transcription factor critical for photoreceptor cell development and function in the retina. Discovered in the mid-1990s, CRX belongs to the homeodomain protein family and is predominantly expressed in retinal photoreceptors (rods and cones) and the pineal gland. It regulates the transcription of genes essential for phototransduction, including opsins and components of the visual cycle. Mutations in the CRX gene are linked to inherited retinal diseases, such as Leber congenital amaurosis (LCA), cone-rod dystrophy, and retinitis pigmentosa, highlighting its role in maintaining retinal health. CRX antibodies are vital tools in research, enabling detection of CRX expression via techniques like immunohistochemistry, Western blotting, and immunofluorescence. These studies help elucidate CRX's spatial and temporal expression patterns during retinal development, its interactions with other photoreceptor-specific factors, and its dysfunction in disease models. Additionally, CRX antibodies aid in diagnosing CRX-related retinopathies and evaluating gene therapy approaches targeting CRX mutations. Their application extends to studying circadian rhythm mechanisms in the pineal gland, where CRX influences melatonin regulation. Overall, CRX antibodies are indispensable for advancing understanding of retinal biology, disease pathogenesis, and therapeutic development.